Understanding CCP-IgG: reference ranges, positive and negative results

CCP-IgG refers to antibodies against cyclic citrullinated peptides. The test helps investigate rheumatoid arthritis, particularly when someone has symptoms of joint inflammation. A positive result is an important clue, but it is not a diagnosis on its own. A negative result does not rule out the disease.

What CCP-IgG measures and why the antibody class matters

IgG is a common class of antibody in the blood. A CCP-IgG test does not measure all of your IgG, however. It measures a particular group: antibodies that bind to the citrullinated peptides used in the test. These belong to the broader family of ACPA, or anti-citrullinated protein antibodies.

Clinical anti-CCP tests were developed to detect an autoimmune response that is especially useful in identifying rheumatoid arthritis, often shortened to RA. One of the early foundational tests specifically measured IgG antibodies. In practice, a clinician requesting “anti-CCP” often means this test. Original test study.

The term IgG does not tell you how many years an immune response has been present. The simple idea that “IgM means acute and IgG means chronic” is too crude for interpreting autoimmune findings. What matters is the target of the antibody and the clinical significance established for that particular test. Biochemical and clinical review.

Reference ranges for anti-CCP-IgG

Results may be reported in U/mL or in units defined by the assay. For example, Mayo Clinic Laboratories reports its CCP-IgG test in U: below 20.0 is negative, 20.0–39.9 weakly positive, 40.0–59.9 positive, and 60.0 or above strongly positive. These are the categories for a particular test, not a universal scale for every CCP2 or CCP3 assay. Laboratory reference ranges.

Always read the limits on your own report. A number from a different test system cannot simply be assigned the same category. The cutoff is determined by the method; it is not an “optimal level” that changes from person to person.

The antibody categories in the 2010 ACR/EULAR classification criteria are a separate matter. There, low positive means above the upper limit of normal but no more than three times that limit. High positive means more than three times the limit. These categories contribute two and three points, respectively. “Greater than zero” is therefore not a correct definition of low positive. Original criteria.

If a laboratory’s upper limit is 20 U, for example, exactly 60 U is not more than three times that limit. The laboratory may already call the result “strongly positive,” while the classification criteria use their own mathematical boundary. The labels should not be treated as interchangeable.

What a positive CCP-IgG result can tell you

Its value for diagnosis

Anti-CCP is relatively specific for RA. In a systematic review, cohort studies of the CCP2 test in early RA, with symptoms for less than two years, had a pooled sensitivity of 57% and specificity of 96%. Sensitivity describes how often the test detects the disease; specificity describes how often it is negative in people without it. The estimates depend on the test generation, disease stage, and people studied. They are not fixed properties of every laboratory assay. Diagnostic review.

A separate meta-analysis reported a positive likelihood ratio of about 12, more precisely 12.46. That number describes how much a positive result changes the odds of disease from their starting point. It does not mean “12 times more certain to have RA.” The same positive test has a different meaning in someone with characteristic joint findings than in someone screened incidentally without symptoms. The likelihood ratio comes from the Nishimura meta-analysis; a further systematic review examined anti-CCP’s diagnostic and predictive value.

Direct comparisons found high specificity for anti-CCP-IgG relative to different rheumatoid factor antibody classes. Rheumatoid factor, or RF, and anti-CCP can nevertheless provide complementary information because not everyone with RA tests positive for both. Direct comparison.

How the number contributes to classification

The ACR/EULAR criteria combine joint involvement, antibody results, inflammatory markers, and symptom duration. They apply to people with at least one clinically swollen joint that is not better explained by another condition. Six out of ten points meets the classification threshold. This is not a self-test for people without symptoms.

Which joints are affected matters. A high antibody level plus “three swollen joints” does not have the same significance regardless of where those joints are. Small and large joints receive different weights. Symptoms lasting at least six weeks also contribute a point. The criteria help organize a professional assessment; they do not replace it.

What it may mean for the course of RA

In people who already have RA, several studies have linked anti-CCP positivity to greater subsequent joint damage on X-rays. One study followed people with recent-onset RA for six years. Other early-RA cohorts examined the relationship between antibody levels and later radiographic findings. Six-year follow-up, early RA study.

Higher antibody titers may also provide prognostic information when arthritis has not yet been clearly classified. In a prospective two-year study, antibody levels were associated with the time to an RA diagnosis. This describes patterns across groups, not an unchangeable future for an individual. Treatment and other features of the illness still matter. Undifferentiated arthritis study.

A positive result before symptoms begin

Anti-CCP can become detectable years before clinical symptoms appear. Studies of stored blood samples show this. In one blood-donor study, IgM rheumatoid factor and/or anti-CCP antibodies were detected a median of 4.5 years before symptoms began in people who later developed RA. That interval concerns either of those antibodies, not anti-CCP alone. Looking backward at people who eventually developed RA does not mean every symptom-free person with a positive result today will develop it within that time. Blood-donor study, another cohort.

What a negative CCP-IgG result means

It does not rule out RA

A substantial proportion of people with RA have no detectable anti-CCP antibodies. If someone has characteristic inflammatory joint swelling, the investigation should continue despite a negative result.

“Anti-CCP negative” also does not automatically mean “seronegative RA”: some people test positive for RF. Seronegative usually refers to the absence of both RF and ACPA. These forms of RA can still be active and require treatment.

The starting probability and the test’s limits

When the clinical likelihood of RA is low, a negative result can be reassuring. In someone with typical inflammatory arthritis, it may reduce suspicion, but not enough to confidently exclude the disease. Examination, RF testing, and sometimes imaging remain important.

A standard test also does not capture every possible ACPA response. Research into different antibody targets shows that some antibodies can appear before a standard CCP test becomes positive. This helps explain the biological variation. It is not a reason to request a research antibody panel after every negative test. ACPA profiles, preclinical multiplex study.

How the test is done

What sample is needed?

Blood is usually drawn from a vein, and the serum is tested. One established method is ELISA: synthetic cyclic peptides bind matching antibodies, and a second, labeled antibody makes that binding measurable. Modern laboratories may use other validated immunoassay platforms.

Do you need to fast?

Fasting is not usually required for anti-CCP alone. Other tests ordered at the same appointment may have different requirements, so follow the laboratory’s instructions. Hospital laboratory guidance.

How long do results take?

Results often take a few days. Mayo Clinic Laboratories, for example, lists two to three days from receipt of the sample. Shipping and the laboratory’s schedule can change the overall wait. RF, CRP, erythrocyte sedimentation rate, and a complete blood count can be collected at the same appointment, although different tubes may be needed. Laboratory turnaround time.

CCP2 and CCP3

The test generations use different combinations of antigens. Much of the clinical literature is based on CCP2. Studies describe differences in sensitivity for CCP3 in some settings, but that does not establish one test as better for every patient. Results from different platforms are not directly interchangeable.

What can affect interpretation?

Early disease can be harder to detect. A negative result at the outset does not exclude a later change, but that does not make frequent repeat testing necessary without a new clinical reason.

Smoking and certain HLA gene variants are associated with ACPA-positive RA. One proposed model connects citrullination at mucosal surfaces with genetically influenced immune recognition. It offers a possible explanation for how the disease develops, not a complete account of every individual result. Mechanistic model.

Positive anti-CCP results have also been described in other illnesses, including tuberculosis. That possibility matters when the clinical circumstances fit; it does not make tuberculosis the default explanation for an unexpected positive test. Tuberculosis study.

Disease-modifying antirheumatic drugs, or DMARDs, and biologic therapies can change antibody titers in some studies. Even so, anti-CCP levels often remain relatively stable and are not a reliable substitute for assessing current joint inflammation. Switching laboratory platforms can also create an apparent change in results.

Which other tests may be useful?

RF adds antibody information. CRP and erythrocyte sedimentation rate provide clues about inflammation, but they can be normal in active RA and elevated in other conditions. The joint examination remains the point of reference.

Total IgG can be useful for a specific question, such as a suspected immunoglobulin disorder. It measures something different and is not automatically needed alongside every anti-CCP test. An ANA test should likewise address a particular possible diagnosis, rather than being ordered as part of a blanket additional panel.

When to seek a timely assessment

A clearly positive result together with persistent inflammatory joint symptoms warrants a timely rheumatology assessment. So do convincing joint findings despite negative antibody tests. A diagnosis should neither rest entirely on one number nor be unnecessarily delayed because a test is negative.

Someone with a positive result but no symptoms can agree on an individual follow-up plan. Family history, smoking, and other features may help shape it. Studies of repeated antibody measurements provide prognostic information, but do not establish a need for frequent anti-CCP monitoring in everyone. Serial measurement study.

Frequently asked questions

What does “CCP-IgG” mean on my report?

It names the antibody class and its target: IgG against cyclic citrullinated peptides. It usually refers to the clinical anti-CCP test, not your total IgG concentration.

What is a normal result?

That depends on the assay. Below 20 U is one laboratory’s example of a negative result, not a universal cutoff. Use the ranges printed on your own report.

What does a high result mean?

Alongside compatible joint findings, it can support an RA diagnosis and provide information about future risk. It does not directly show how much inflammation you have today or what damage will inevitably occur.

What does a positive result mean if I have no symptoms?

It may indicate an autoimmune response before clinical disease appears. It does not confirm RA or make the future certain. A professional assessment can help establish an appropriate follow-up plan.

Can the test be positive without RA?

Yes. Positive results can occur in other conditions, and borderline or unexpected findings also need interpretation. The starting likelihood of RA affects what a positive result means; specificity is not the same as your individual probability of having the disease.

What is the difference between low and high positive?

In the ACR/EULAR classification, low positive means above the normal limit but no more than three times that limit. High positive is above that range. Laboratory labels such as weak, moderate, or strong may use different categories.

Do I need regular repeat tests?

Not routinely to monitor disease activity. Repeating a test may be useful for a borderline result, a new clinical situation, or a specific prognostic question. Timing should be decided individually.

Which other tests go with it?

RF, CRP, or erythrocyte sedimentation rate are often helpful, depending on the symptoms. Other immune markers and imaging are chosen for specific reasons. No additional panel replaces examining the joints.

Sources

• Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, van Venrooij WJ (2000). The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis and rheumatism, 43(1), 155-63. https://doi.org/10.1002/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3. Source
• Nijenhuis S, Zendman AJ, Vossenaar ER, Pruijn GJ, vanVenrooij WJ (2004). Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of an RA-specific marker. Clinica chimica acta; international journal of clinical chemistry, 350(1-2), 17-34. https://doi.org/10.1016/j.cccn.2004.07.016. Source
• Whiting PF, Smidt N, Sterne JA, Harbord R, Burton A, Burke M, Beynon R, Ben-Shlomo Y, Axford J, Dieppe P (2010). Systematic review: accuracy of anti-citrullinated Peptide antibodies for diagnosing rheumatoid arthritis. Annals of internal medicine, 152(7), 456-64; W155-66. https://doi.org/10.7326/0003-4819-152-7-201004060-00010. Source
• Avouac J, Gossec L, Dougados M (2006). Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Annals of the rheumatic diseases, 65(7), 845-51. https://doi.org/10.1136/ard.2006.051391. Source
• Vallbracht I, Rieber J, Oppermann M, Förger F, Siebert U, Helmke K (2004). Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis. Annals of the rheumatic diseases, 63(9), 1079-84. https://doi.org/10.1136/ard.2003.019877. Source
• McInnes IB, Schett G (2011). The pathogenesis of rheumatoid arthritis. The New England journal of medicine, 365(23), 2205-19. https://doi.org/10.1056/NEJMra1004965. Source
• Radner H, Neogi T, Smolen JS, Aletaha D (2014). Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review. Annals of the rheumatic diseases, 73(1), 114-23. https://doi.org/10.1136/annrheumdis-2013-203284. Source
• Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, van den Hoogen FH, van’t Hof M, van de Putte LB, van Rijswijk MH, van Venrooij WJ, van Riel PL (2000). The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis and rheumatism, 43(8), 1831-5. https://doi.org/10.1002/1529-0131(200008)43:8<1831::AID-ANR19>3.0.CO;2-6. Source
• Forslind K, Ahlmén M, Eberhardt K, Hafström I, Svensson B, BARFOT Study Group (2004). Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Annals of the rheumatic diseases, 63(9), 1090-5. https://doi.org/10.1136/ard.2003.014233. Source
• Berglin E, Johansson T, Sundin U, Jidell E, Wadell G, Hallmans G, Rantapää-Dahlqvist S (2006). Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Annals of the rheumatic diseases, 65(4), 453-8. https://doi.org/10.1136/ard.2005.041376. Source
• Bizzaro N, Bartoloni E, Morozzi G, Manganelli S, Riccieri V, Sabatini P, Filippini M, Tampoia M, Afeltra A, Sebastiani G, Alpini C, Bini V, Bistoni O, Alunno A, Gerli R, Forum Interdisciplinare per la Ricerca nelle Malattie Autoimmuni (FIRMA Group) (2013). Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study. Arthritis research & therapy, 15(1), R16. https://doi.org/10.1186/ar4148. Source
• Rantapää-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, Sundin U, van Venrooij WJ (2003). Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis and rheumatism, 48(10), 2741-9. https://doi.org/10.1002/art.11223. Source
• Nielen MM, van Schaardenburg D, Reesink HW, van de Stadt RJ, van der Horst-Bruinsma IE, de Koning MH, Habibuw MR, Vandenbroucke JP, Dijkmans BA (2004). Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis and rheumatism, 50(2), 380-6. https://doi.org/10.1002/art.20018. Source
• Quinn MA, Gough AK, Green MJ, Devlin J, Hensor EM, Greenstein A, Fraser A, Emery P (2006). Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology (Oxford, England), 45(4), 478-80. https://doi.org/10.1093/rheumatology/kei203. Source
• Willemze A, Böhringer S, Knevel R, Levarht EW, Stoeken-Rijsbergen G, Houwing-Duistermaat JJ, van der Helm-van Mil AH, Huizinga TW, Toes RE, Trouw LA (2012). The ACPA recognition profile and subgrouping of ACPA-positive RA patients. Annals of the rheumatic diseases, 71(2), 268-74. https://doi.org/10.1136/annrheumdis-2011-200421. Source
• Brink M, Hansson M, Mathsson L, Jakobsson PJ, Holmdahl R, Hallmans G, Stenlund H, Rönnelid J, Klareskog L, Rantapää-Dahlqvist S (2013). Multiplex analyses of antibodies against citrullinated peptides in individuals prior to development of rheumatoid arthritis. Arthritis and rheumatism, 65(4), 899-910. https://doi.org/10.1002/art.37835. Source
• Cms. (n.d.). Clinical Laboratory Improvement Amendments (CLIA). https://cms.gov/medicare/quality/clinical-laboratory-improvement-amendments. Source
• Klareskog L, Stolt P, Lundberg K, Källberg H, Bengtsson C, Grunewald J, Rönnelid J, Harris HE, Ulfgren AK, Rantapää-Dahlqvist S, Eklund A, Padyukov L, Alfredsson L (2006). A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis and rheumatism, 54(1), 38-46. https://doi.org/10.1002/art.21575. Source
• Londhey V, Shah MM (2016). Anti CCP Antibodies in Tuberculosis. The Journal of the Association of Physicians of India, 64(5), 26-28. https://pubmed.ncbi.nlm.nih.gov/27735145/. Source
• Meyer O, Nicaise-Roland P, Santos MD, Labarre C, Dougados M, Goupille P, Cantagrel A, Sibilia J, Combe B (2006). Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis. Arthritis research & therapy, 8(2), R40. https://doi.org/10.1186/ar1896. Source
• American College of Rheumatology. (n.d.). Rheumatoid Arthritis Clinical Practice Guidelines. https://rheumatology.org/rheumatoid-arthritis-guideline. Source
• Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, Saigo K, Morinobu A, Koshiba M, Kuntz KM, Kamae I, Kumagai S (2007). Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Annals of internal medicine, 146(11), 797-808. https://doi.org/10.7326/0003-4819-146-11-200706050-00008. Source